Aker Biomarine AS

AKBM · Oslo Børs · Consumer defensive

122.00NOK +6.6%last day

Price as of 1 October 2026

The price over the past year, with dividends: +37.4%

Performance

1 month

−7.6%

1 year

+37.4%

3 years, per year

+76.6%

5 years, per year

+37.4%

Largest fall, 3 years

−71.1%

Below the peak now

−9.9%

Volatility, 1 year

33.9%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

7.7

Dividend yield

0.0%

Return on equity

+0.2%

Net margin

0.0%

Market value

1.1 bn USD

Quality, value and trend

Where Aker Biomarine stands against every Nordic stock today. 100 is best.

Quality7

Profitability and a sound balance sheet over time. Better than 7% of Nordic stocks.

Value25

The price measured against earnings, assets and cash flow. Better than 25% of Nordic stocks.

Trend92

The price development over the past year. Better than 92% of Nordic stocks.

Combined32

Quality, value and trend together. Better than 32% of Nordic stocks.

About Aker Biomarine

Aker Biomarine AS is a company in consumer defensive, listed on Oslo Børs. The share trades in NOK. It has around 260 employees.

Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name. The Consumer Health Products segment sells processed and packaged krill, fish, and plants derived raw materials to retailers in the United States.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis